Tyme Technologies (TYME) Misses Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
TYME Technologies, Inc. Provides Business Update and Announces Fiscal First Quarter 2022 Financial and Operating Results
August 10, 2021 6:45 AM EDTCompleted strategic review, identifying breast cancer, second-line pancreatic cancer, high-risk sarcomas as priority clinical settings
- Announced OASIS breast cancer trial, a multicenter Phase II single-arm, open-label study of SM-88 used with methoxsalen, phenytoin, and sirolimus (MPS) in metastatic HR+/HER2- breast cancer, with Georgetown University
- Granted U.S. patent claims covering use of tyrosine-based drug delivery method to treat cancer -
Appointed acting Chief Medical Officer Dr. Jan M. Van Tornout, and Chief Financial Officer, Frank Porfido -
... More
